BioSpace News Archive

Oncoceutics announced that the USPTO issued patent #9,845,324, providing the company with composition of matter protection for ONC212 and several additional small molecules derived from Oncoceutics’ lead compound ONC201.

ImmunoPrecise is pleased to announce the appointment of Dr. Robert Burke to the Company’s Board of Directors.

Allergan and Paratek Pharma today announced that the FDA has accepted a NDA to review Seysara for the treatment of moderate to severe acne vulgaris in patients 9 years of age and older.

WITH and Bpifrance have co-organized Vive la Biotech 2018! to be held in San Francisco on Sunday, January 7, 2018.

CE marking for Easylog is a significant step for BIOCORP. Our ambition is to develop and market innovative devices boosting compliance, a key factor for the successful treatment of chronic conditions such as diabetes.

This portion of the Company’s Phase 1 clinical trial is an open-label, multi-center nonrandomized dose escalation study evaluating the safety and MTD and recommended Phase 2 dose of MVT-5873 in combination with a standard of care chemotherapy in subjects with pancreatic and other CA19-9 positive malignancies.

The V-Sensor health sensor and app uses a modification of the classical medical technique of Riva-Rocci to measure blood pressure.

An Extraordinary General Meeting of Nordic Nanovector was held today on 20 December 2017 in Oslo, Norway.

In conjunction with this collaboration, Bristol-Myers Squibb also made an equity investment in TARIS.

Amneal Pharmaceuticals has launched sevelamer carbonate tablets, 800 mg, in 270-count bottles.